The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. It operates in five segments: Allstate Protection; Run-off Property-Liability; Protection Services; Allstate Health and Benefits; and Corporate and Other. The company offers private passenger auto, homeowners, personal lines, and commercial insurance products through agents, contact centers, and online; and property and casualty insurance products. It also provides consumer product protection plans, device and mobile data collection services, and analytic solutions using automotive telematics information, roadside assistance, and protection plans; and insurance products, such as identity protection and restoration through Allstate Protection Plans, Allstate Dealer Services, Allstate Roadside, Arity, and Allstate Identity Protection brands. In addition, the company offers life, accident, critical illness, hospital indemnity, short-term disability, and other health insurance products; self-funded stop-loss and fully insured group health products to employers; medicare supplement, ancillary products, and short-term medical insurance to individuals through independent agents, owned agencies, benefits brokers, and Allstate exclusive agents. Further, it offers automotive protection; vehicle service contracts, guaranteed asset protection, road hazard tires and wheels, and paintless dent repair protection; and roadside assistance, mobility data collection services, and analytic solutions using automotive telematics information, identity theft protection, and remediation services. The Allstate Corporation was founded in 1931 and is headquartered in Northbrook, Illinois.

Allstate Corporation (The)

Analysts have been eager to weigh in on the Financial sector with new ratings on Ethos Technologies Inc. Class A (LIFE) and Allstate (ALL). Ethos T...

Analysts Offer Insights on Financial Companies: Ethos Technologies Inc. Class A (LIFE) and Allstate (ALL)

In a report released today, from Macquarie maintained a Hold rating on Atlantic Lithium, with a price target of A$0.35. Currently, the analyst cons...

Macquarie Remains a Hold on Atlantic Lithium (ALL)

Using the&nbsp;TipRanks Stock Screener Tool, we identified three companies that have low&nbsp;Price-to-Earnings (P/E) ratios&nbsp;and hold a “Stron...

3 Best Low P/E Stocks Rated ‘Strong Buy’ with Over 20% Upside

Alleima AB ( ($SE:ALLEI) ) has provided an update. Alleima has secured a major order worth approximately SEK 995 million to supply advanced umbilic...

Alleima Wins SEK 995 Million Umbilical Tubing Order for Major Indonesian Offshore Project

Analysts have been eager to weigh in on the Industrial Goods sector with new ratings on APi Group (APG) and Allegion (ALLE). APi Group (APG) Bank o...

Analysts Offer Insights on Industrial Goods Companies: APi Group (APG) and Allegion (ALLE)

Wells Fargo analyst Gabrial Hajde maintained a Buy rating on Ball yesterday and set a price target of $71.00. The company’s shares closed yesterday...

Wells Fargo Keeps Their Buy Rating on Ball (BALL)

The latest update is out from Allegion ( ($ALLE) ). On June 4, 2026, Allegion shareholders met in Dublin for the company’s 2026 annual general meet...

Allegion Shareholders Reaffirm Board, Pay and Capital Flexibility

Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Eaton (ETN) and Allegion (ALLE). Eaton (ETN)...

Analysts Conflicted on These Industrial Goods Names: Eaton (ETN) and Allegion (ALLE)

Barclays analyst Alex Scott maintained a Sell rating on Allstate on June 4 and set a price target of $203.00. The company’s shares closed yesterday...

Barclays Sticks to Its Sell Rating for Allstate (ALL)

Allarity Therapeutics ( ($ALLR) ) just unveiled an update. Effective June 1, 2026, Allarity Therapeutics entered into an Amended and Restated Manag...

Allarity Therapeutics Updates CEO Management and Compensation Agreement

In a report released today, from Macquarie maintained a Hold rating on Atlantic Lithium, with a price target of A$0.32. Currently, the analyst cons...

Macquarie Sticks to Its Hold Rating for Atlantic Lithium (ALL)

Analysts have been eager to weigh in on the Consumer Cyclical sector with new ratings on Ball (BALL) and BRP (DOO). Ball (BALL) RBC Capital analyst...

Analysts Offer Insights on Consumer Cyclical Companies: Ball (BALL) and BRP (DOO)

In a report released today, Michael Roxland from Truist Financial maintained a Buy rating on Ball, with a price target of $77.00. Roxland covers th...

Ball (BALL) Receives a Buy from Truist Financial

Allogene Therapeutics ( ($ALLO) ) has issued an announcement. On May 28, 2026, Allogene Therapeutics’ board appointed Zachary Roberts, M.D., Ph.D.,...

Allogene Therapeutics Names Zachary Roberts as New CEO

There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Snowflake (SNOW) and Allot (ALLT) with bullish senti...

Analysts Are Bullish on These Technology Stocks: Snowflake (SNOW), Allot (ALLT)

In a report released today, Paul Newsome from Piper Sandler maintained a Buy rating on Allstate, with a price target of $268.00. According to TipRa...

Piper Sandler Sticks to Their Buy Rating for Allstate (ALL)

Analysts have been eager to weigh in on the Financial sector with new ratings on IGM Financial (IGIFF) and Allstate (ALL). IGM Financial (IGIFF) In...

Analysts Conflicted on These Financial Names: IGM Financial (OtherIGIFF) and Allstate (ALL)

Citi analyst Adrian Lemme maintained a Buy rating on Aristocrat Leisure yesterday and set a price target of A$61.00. According to TipRanks, Lemme i...

Citi Sticks to Their Buy Rating for Aristocrat Leisure  (ARLUF)

In a report released on May 22, Elyse Greenspan from Wells Fargo maintained a Hold rating on Allstate, with a price target of $243.00. The company’...

Current Quarter	$4.66	Next Quarter	$5.47
Current Year	$29.43	Next Year	$26.38
QoQ Growth	+17.4%	YoY Growth	-10.4%
3Y EPS CAGR	N/A	Target Price	$242.50
Consensus	Buy	Upside	+9.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALL	$221.17	-0.22%	5.02M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALL	$221.17	-0.2%	5.02M
3
4
5
6

ALL

ALL

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Allstate Corporation (The) Data in Excel

Get Allstate Corporation (The) Data in Excel